Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

Diabetes Care
Julio RosenstockGeorge Dailey

Abstract

To evaluate the efficacy and safety of add-on insulin glargine versus rosiglitazone in insulin-naïve patients with type 2 diabetes inadequately controlled on dual oral therapy with sulfonylurea plus metformin. In this 24-week multicenter, randomized, open-label, parallel trial, 217 patients (HbA(1c) [A1C] 7.5-11%, BMI >25 kg/m(2)) on > or =50% of maximal-dose sulfonylurea and metformin received add-on insulin glargine 10 units/day or rosiglitazone 4 mg/day. Insulin glargine was forced-titrated to target fasting plasma glucose (FPG) < or =5.5-6.7 mmol/l (< or =100-120 mg/dl), and rosiglitazone was increased to 8 mg/day any time after 6 weeks if FPG was >5.5 mmol/l. A1C improvements from baseline were similar in both groups (-1.7 vs. -1.5% for insulin glargine vs. rosiglitazone, respectively); however, when baseline A1C was >9.5%, the reduction of A1C with insulin glargine was greater than with rosiglitazone (P < 0.05). Insulin glargine yielded better FPG values than rosiglitazone (-3.6 +/- 0.23 vs. -2.6 +/- 0.22 mmol/l; P = 0.001). Insulin glargine final dose per day was 38 +/- 26 IU vs. 7.1 +/- 2 mg for rosiglitazone. Confirmed hypoglycemic events at plasma glucose <3.9 mmol/l (<70 mg/dl) were slightly greater for the insulin g...Continue Reading

References

Mar 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·M R TaskinenH Yki-Järvinen
Dec 24, 1997·Diabetes Care·T P GilmerW A Rush
Feb 15, 2001·JAMA : the Journal of the American Medical Association·E H WagnerL C Grothaus
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Silvio E Inzucchi
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Feb 19, 2004·The American Journal of Medicine·Andrew J Ahmann, Matthew C Riddle
Jun 29, 2004·Diabetes Care·Jonathan B BrownAndrew Perry
Jun 29, 2004·Diabetes Care·Mayer B Davidson

❮ Previous
Next ❯

Citations

Jul 31, 2008·Cardiovascular Drugs and Therapy·Hong-Yan LingDuan-Fang Liao
Nov 16, 2013·Current Treatment Options in Cardiovascular Medicine·Elliott M GrovesShaista Malik
Jun 26, 2013·Advances in Therapy·Anthony H Barnett
Nov 5, 2013·Diabetes Research and Clinical Practice·J B McGillS J Fisher
Jan 18, 2008·The New England Journal of Medicine·Ronald B GoldbergDaniel J Drucker
Sep 25, 2007·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Dec 8, 2010·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Jeffry G WeersIan J Smith
Mar 18, 2011·Metabolic Syndrome and Related Disorders·Katherine EspositoDario Giugliano
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Mayer B Davidson
Jul 17, 2008·Diabetes, Obesity & Metabolism·C Mathieu, S Robbrecht
Jul 17, 2008·Diabetes, Obesity & Metabolism·M Davies, K Khunti
Jan 30, 2009·Diabetes, Obesity & Metabolism·Mariëlle J P van Avendonk, Guy E H M Rutten
May 17, 2011·Diabetes, Obesity & Metabolism·A Chaudhuri, P Dandona
Dec 14, 2011·Diabetes, Obesity & Metabolism·S Colagiuri
Jun 28, 2007·International Journal of Clinical Practice. Supplement·M Hanefeld
Jul 1, 2010·Experimental Diabetes Research·Vasiliki Valla
Sep 2, 2010·Cardiovascular Diabetology·L Romayne Kurukulasuriya, James R Sowers
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Stanley S Schwartz
May 14, 2009·Therapeutics and Clinical Risk Management·Zoheir Ezziane
Jun 22, 2007·Vascular Health and Risk Management·Andreas PfütznerThomas Forst
Jul 31, 2007·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Eva M Vivian
Feb 19, 2014·Nature Reviews. Endocrinology·Vivian A Fonseca, Michelle A Haggar
Aug 7, 2009·Wiener klinische Wochenschrift·Bernhard LudvikUNKNOWN Expertengruppe der Osterreichischen Diabetesgesellschaft

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.